WCN26-4808 Treatment of Glycogen Storage Disease Type Ib with Empagliflozin and Angiotensin II Receptor Blockers: A Case Series

Read full text Summarise with VIRAT
Authors: Feng-Jung Yang, Yin‐Hsiu Chien
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Glycogen storage disease type Ib (GSD-Ib) is an ultrarare inborn error of glycogen metabolism caused by biallelic pathogenic variants in SLC37A4, encoding glucose-6-phosphate translocase (G6PT). The disorder manifests with recurrent fasting hypoglycemia, hepatomegaly, neutropenia, neutrophil dysfunction, inflammatory bowel disease (IBD), mucosal lesions, and progressive kidney disease. Accumulation of 1,5-anhydroglucitol-6-phosphate (1,5-AG6P) in granulocytes induces energy deficiency and apoptosis, causing neutropenia and associated complications.

Fields of Study & Subjects

Glycogen Storage Diseases and Myoclonus Metabolism and Genetic Disorders Lysosomal Storage Disorders Research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105123–105123
Publication date
25 March 2026
Language
EN